Nippon Shinyaku Co. Ltd.

09/18/2024 | Press release | Distributed by Public on 09/17/2024 17:34

Nippon Shinyaku and Capricor Therapeutics Execute Letter of Intent for Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in Europe